{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T17:18:10Z","timestamp":1758475090374,"version":"3.37.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"19-20","license":[{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T00:00:00Z","timestamp":1590364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00508-020-01669-y","type":"journal-article","created":{"date-parts":[[2020,5,25]],"date-time":"2020-05-25T16:02:27Z","timestamp":1590422547000},"page":"1070-1075","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis"],"prefix":"10.1007","volume":"133","author":[{"given":"Dijana","family":"Perkovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5282-9633","authenticated-orcid":false,"given":"Marin","family":"Petri\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivona","family":"Bo\u017ei\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarina","family":"Bori\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Marasovi\u0107 Krstulovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mislav","family":"Radi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Du\u0161anka","family":"Martinovi\u0107 Kaliterna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,25]]},"reference":[{"key":"1669_CR1","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.rdc.2015.04.002","volume":"41","author":"EP Stern","year":"2015","unstructured":"Stern\u00a0EP, Denton\u00a0CP. The pathogenesis of systemic sclerosis. Rheum Dis Clin North Am. 2015;41:367\u201382.","journal-title":"Rheum Dis Clin North Am"},{"key":"1669_CR2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12016-007-8009-2","volume":"33","author":"N Yazawa","year":"2007","unstructured":"Yazawa\u00a0N, Fujimoto\u00a0M, Tamaki\u00a0K. Recent advances on pathogenesis and therapies in systemic sclerosis. Clin Rev Allergy Immunol. 2007;33:107\u201312.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1669_CR3","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.semarthrit.2007.10.010","volume":"38","author":"YS Gu","year":"2008","unstructured":"Gu\u00a0YS, Kong\u00a0J, Cheema\u00a0GS, Keen\u00a0CL, Wick\u00a0G, Gershwin\u00a0ME. The immunobiology of systemic sclerosis. Semin Arthritis Rheum. 2008;38:132\u201360.","journal-title":"Semin Arthritis Rheum"},{"key":"1669_CR4","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10067-016-3533-1","volume":"36","author":"M Rubio-Rivas","year":"2017","unstructured":"Rubio-Rivas\u00a0M, Moreno\u00a0R, Corbella\u00a0X. Occupational and environmental scleroderma. Systematic review and meta-analysis. Clin Rheumatol. 2017;36:569\u201382.","journal-title":"Clin Rheumatol"},{"key":"1669_CR5","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3389\/fimmu.2015.00272","volume":"6","author":"D Pattanaik","year":"2015","unstructured":"Pattanaik\u00a0D, Brown\u00a0M, Postlethwaite\u00a0BC, Postlethwaite\u00a0AE. Pathogenesis of systemic sclerosis. Front Immunol. 2015;6:272.","journal-title":"Front Immunol"},{"key":"1669_CR6","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/sji.12595","volume":"86","author":"M Walczyk","year":"2017","unstructured":"Walczyk\u00a0M, Paradowska-Gorycka\u00a0A, Olesinska\u00a0M. Epigenetics: the future direction in systemic sclerosis. Scand J Immunol. 2017;86:427\u201335.","journal-title":"Scand J Immunol"},{"key":"1669_CR7","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/03009740510026896","volume":"35","author":"G Valentini","year":"2006","unstructured":"Valentini\u00a0G, Paone\u00a0C, La Montagna\u00a0G, et al. Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease. Scand J Rheumatol. 2006;35:35\u20138.","journal-title":"Scand J Rheumatol"},{"key":"1669_CR8","first-page":"7","volume":"58","author":"S Kundu","year":"2016","unstructured":"Kundu\u00a0S, Paul\u00a0S, Hariprasath\u00a0K, Agarwal\u00a0R, Ghosh\u00a0S, Biswas\u00a0D. Effect of sequential intravenous pulse cyclophosphamide-azathioprine in systemic sclerosis-interstitial lung disease: an open-label study. Indian J Chest Dis Allied Sci. 2016;58:7\u201310.","journal-title":"Indian J Chest Dis Allied Sci"},{"key":"1669_CR9","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/1096-9896(2000)9999:9999<::AID-PATH779>3.0.CO;2-8","volume":"193","author":"MM Seyger","year":"2001","unstructured":"Seyger\u00a0MM, van den Hoogen\u00a0FH, van Vlijmen-Willems\u00a0IM, van de Kerkhof\u00a0PC, de Jong\u00a0EM. Localized and systemic scleroderma show different histological responses to methotrexate therapy. J\u00a0Pathol. 2001;193:511\u20136.","journal-title":"J Pathol"},{"key":"1669_CR10","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.3899\/jrheum.111229","volume":"39","author":"FA Mendoza","year":"2012","unstructured":"Mendoza\u00a0FA, Nagle\u00a0SJ, Lee\u00a0JB, Jimenez\u00a0SA. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset. J\u00a0Rheumatol. 2012;39:1241\u20137.","journal-title":"J Rheumatol"},{"key":"1669_CR11","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O, Fransen\u00a0J, Avouac\u00a0J, Becker\u00a0M, Kulak\u00a0A, Allanore\u00a0Y, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76:1327\u201339.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR12","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","volume":"176","author":"DP Tashkin","year":"2007","unstructured":"Tashkin\u00a0DP, Elashoff\u00a0R, Clements\u00a0PJ, Roth\u00a0MD, Furst\u00a0DE, Silver\u00a0RM, et al. Effects of 1\u2011year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176:1026\u201334.","journal-title":"Am J Respir Crit Care Med"},{"key":"1669_CR13","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna\u00a0D, Denton\u00a0CP, Jahreis\u00a0A, van Laar\u00a0JM, Frech\u00a0TM, Anderson\u00a0ME, et\u00a0al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a\u00a0phase 2, randomised, controlled trial. Lancet. 2016;387:2630\u201340.","journal-title":"Lancet"},{"key":"1669_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00281-015-0551-z","volume":"38","author":"O Distler","year":"2016","unstructured":"Distler\u00a0O, Cozzio\u00a0A. Systemic sclerosis and localized scleroderma\u2014current concepts and novel targets for therapy. Semin Immunopathol. 2016;38:87\u201395.","journal-title":"Semin Immunopathol"},{"key":"1669_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/6064830","author":"AT Dantas","year":"2016","unstructured":"Dantas\u00a0AT, Gon\u00e7alves\u00a0SM, de Almeida\u00a0AR, Gon\u00e7alves\u00a0RS, Sampaio\u00a0MC, Vilar\u00a0KM, et al. Reassessing the role of the active TGF-\u03b21 as a biomarker in systemic sclerosis: association of serum levels with clinical manifestations. Dis Markers. 2016; https:\/\/doi.org\/10.1155\/2016\/6064830.","journal-title":"Dis Markers"},{"key":"1669_CR16","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1093\/rheumatology\/kev117","volume":"54","author":"JM van Laar","year":"2015","unstructured":"van Laar\u00a0JM, Naraghi\u00a0K, Tyndall\u00a0A. Haematopoietic stem cell transplantation for poor-prognosis systemic sclerosis. Rheumatology (Oxford). 2015;54:2126\u201333.","journal-title":"Rheumatology (Oxford)"},{"key":"1669_CR17","first-page":"198","volume":"106","author":"L Host","year":"2017","unstructured":"Host\u00a0L, Nikpour\u00a0M, Calderone\u00a0A, Cannell\u00a0P, Roddy\u00a0J. Autologous stem cell transplantation in systemic sclerosis: a\u00a0systematic review. Clin Exp Rheumatol. 2017;106:198\u2013207.","journal-title":"Clin Exp Rheumatol"},{"key":"1669_CR18","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/vox.12467","volume":"112","author":"B Mayer","year":"2017","unstructured":"Mayer\u00a0B, Depr\u00e9\u00a0F, Ringel\u00a0F, Salama\u00a0A. New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia. Vox Sang. 2017;112:64\u20139.","journal-title":"Vox Sang"},{"key":"1669_CR19","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1007\/s10067-015-3059-y","volume":"34","author":"E Vermaak","year":"2015","unstructured":"Vermaak\u00a0E, Tansley\u00a0SL, McHugh\u00a0NJ. The evidence for immunotherapy in dermatomyositis and polymyositis: a\u00a0systematic review. Clin Rheumatol. 2015;34:2089\u201395.","journal-title":"Clin Rheumatol"},{"key":"1669_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1006\/jaut.1993.1056","volume":"6","author":"V Hurez","year":"1993","unstructured":"Hurez\u00a0V, Kaveri\u00a0SV, Kazatchkine\u00a0MD. Normal polyspecific immunoglobulin G (IVIg) in the treatment of autoimmune diseases. J\u00a0Autoimmun. 1993;6:675\u201381.","journal-title":"J Autoimmun"},{"key":"1669_CR21","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10875-007-9088-9","volume":"27","author":"VS Negi","year":"2007","unstructured":"Negi\u00a0VS, Elluru\u00a0S, Sib\u00e9ril\u00a0S, Graff-Dubois\u00a0S, Mouthon\u00a0L, Kazatchkine\u00a0MD, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J\u00a0Clin Immunol. 2007;27:233\u201345.","journal-title":"J Clin Immunol"},{"key":"1669_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1503\/cmaj.130375","volume":"187","author":"L Gilardin","year":"2015","unstructured":"Gilardin\u00a0L, Bayry\u00a0J, Kaveri\u00a0SV. Intravenous immunoglobulin as clinical immune-modulating therapy. CMAJ. 2015;187:257\u201364.","journal-title":"CMAJ"},{"key":"1669_CR23","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1007\/s10875-010-9395-4","volume":"30","author":"S Gupta","year":"2010","unstructured":"Gupta\u00a0S. Antibodies: basic mechanisms and emerging concepts. J\u00a0Clin Immunol. 2010;30:S1\u2013S3.","journal-title":"J Clin Immunol"},{"key":"1669_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2012.09.010","volume":"69","author":"H Kudo","year":"2013","unstructured":"Kudo\u00a0H, Jinnin\u00a0M, Yamane\u00a0K, Makino\u00a0T, Kajihara\u00a0I, Makino\u00a0K, et al. Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J\u00a0Dermatol Sci. 2013;69:77\u201380.","journal-title":"J Dermatol Sci"},{"issue":"11","key":"1669_CR25","first-page":"2559","volume":"14","author":"CG Katsiari","year":"2018","unstructured":"Katsiari\u00a0CG, Simopoulou\u00a0T, Alexiou\u00a0I, Sakkas\u00a0LI. Immunotherapy of systemic sclerosis. Hum Vaccin Immunother. 2018;14(11):2559\u201367.","journal-title":"Hum Vaccin Immunother"},{"key":"1669_CR26","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","volume":"44","author":"Y Asano","year":"2005","unstructured":"Asano\u00a0Y, Ihn\u00a0H, Asashima\u00a0N, Yazawa\u00a0N, Mimura\u00a0Y, Jinnin\u00a0M, et al. A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology (Oxford). 2005;44:824\u20136.","journal-title":"Rheumatology (Oxford)"},{"key":"1669_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy\u00a0Y, Amital\u00a0H, Langevitz\u00a0P, Nacci\u00a0F, Righi\u00a0A, Conforti\u00a0L, et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheum. 2004;50:1005\u20137.","journal-title":"Arthritis Rheum"},{"key":"1669_CR28","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara\u00a0K, Ihn\u00a0H, Sato\u00a0S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013;31:151\u20136.","journal-title":"Clin Exp Rheumatol"},{"key":"1669_CR29","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3899\/jrheum.140833","volume":"42","author":"CL Poelman","year":"2015","unstructured":"Poelman\u00a0CL, Hummers\u00a0LK, Wigley\u00a0FM, Anderson\u00a0C, Boin\u00a0F, Shah\u00a0AA. Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J\u00a0Rheumatol. 2015;42:236\u201342.","journal-title":"J Rheumatol"},{"key":"1669_CR30","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00296-011-1967-y","volume":"32","author":"H Poormoghim","year":"2012","unstructured":"Poormoghim\u00a0H, Moradi Lakeh\u00a0M, Mohammadipour\u00a0M, Sodagari\u00a0F, Toofaninjed\u00a0N. Cyclophosphamide for scleroderma lung disease: a\u00a0systematic review and meta-analysis. Rheumatol Int. 2012;32:2431\u201344.","journal-title":"Rheumatol Int"},{"issue":"11","key":"1669_CR31","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen\u00a0F, Khanna\u00a0D, Fransen\u00a0J, Johnson\u00a0SR, Baron\u00a0M, Tyndall\u00a0A, et\u00a0al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"key":"1669_CR32","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/ard.2006.060111","volume":"66","author":"F Nacci","year":"2007","unstructured":"Nacci\u00a0F, Righi\u00a0A, Conforti\u00a0ML, Miniati\u00a0I, Fiori\u00a0G, Martinovic\u00a0D, et\u00a0al. Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: a\u00a0pilot study. Ann Rheum Dis. 2007;66:977\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3109\/08916934.2015.1104671","volume":"49","author":"Z Zhou","year":"2016","unstructured":"Zhou\u00a0Z, Qiao\u00a0Z, Li\u00a0H, Luo\u00a0N, Zhang\u00a0X, Xue\u00a0F, et al. Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: results of a\u00a0prospective study including 167 cases. Autoimmunity. 2016;49:50\u20137.","journal-title":"Autoimmunity"},{"key":"1669_CR34","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/MBC.0b013e3283401490","volume":"21","author":"YH Qin","year":"2010","unstructured":"Qin\u00a0YH, Zhou\u00a0TB, Su\u00a0LN, Lei\u00a0FY, Zhao\u00a0YJ, Huang\u00a0WF. The efficacy of different dose intravenous immunoglobulin in treating acute idiopathic thrombocytopenic purpura: a\u00a0meta-analysis of 13 randomized controlled trials. Blood Coagul Fibrinolysis. 2010;21:713\u201321.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"1669_CR35","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.autrev.2017.02.008","volume":"16","author":"S Sanges","year":"2017","unstructured":"Sanges\u00a0S, Rivi\u00e8re\u00a0S, Mekinian\u00a0A, Martin\u00a0T, Le Quellec\u00a0A, Chatelus\u00a0E, et\u00a0al. Intravenous immunoglobulins in systemic sclerosis: data from a\u00a0French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev. 2017;16:377\u201384.","journal-title":"Autoimmun Rev"},{"key":"1669_CR36","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","volume":"55","author":"J Raja","year":"2016","unstructured":"Raja\u00a0J, Nihtyanova\u00a0SI, Murray\u00a0CD, Denton\u00a0CP, Ong\u00a0VH. Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford). 2016;55:115\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"1669_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/ard.62.2.175","volume":"62","author":"H Amital","year":"2003","unstructured":"Amital\u00a0H, Rewald\u00a0E, Levy\u00a0Y, Bar-Dayan\u00a0Y, Manthorpe\u00a0R, Engervall\u00a0P, et al. Fibrosis regression induced by intravenous gammaglobulin treatment. Ann Rheum Dis. 2003;62:175\u20137.","journal-title":"Ann Rheum Dis"},{"key":"1669_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1385\/CRIAI:29:3:321","volume":"29","author":"V Molina","year":"2005","unstructured":"Molina\u00a0V, Blank\u00a0M, Shoenfeld\u00a0Y. Intravenous immunoglobulin and fibrosis. Clin Rev Allergy Immunol. 2005;29:321\u20136.","journal-title":"Clin Rev Allergy Immunol"},{"key":"1669_CR39","first-page":"18","volume":"41","author":"M Cutolo","year":"2016","unstructured":"Cutolo\u00a0M, Sulli\u00a0A, Pizzorni\u00a0C, Paolino\u00a0S, Smith\u00a0V. Systemic sclerosis: markers and targeted treatments. Acta Reumatolog Port. 2016;41:18\u201325.","journal-title":"Acta Reumatolog Port"},{"key":"1669_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.clim.2018.12.006","volume":"199","author":"JP Gomes","year":"2019","unstructured":"Gomes\u00a0JP, Santos\u00a0L, Shoenfeld\u00a0Y. Intravenous immunoglobulin (IVIG) in the vanguard therapy of systemic sclerosis. Clin Immunol. 2019;199:25\u20138.","journal-title":"Clin Immunol"},{"key":"1669_CR41","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12026-014-8615-z","volume":"61","author":"L Cantarini","year":"2015","unstructured":"Cantarini\u00a0L, Rigante\u00a0D, Vitale\u00a0A, Napodano\u00a0S, Sakkas\u00a0LI, Bogdanos\u00a0DP, et\u00a0al. Intravenous immunoglobulins (IVIG) in systemic sclerosis: a\u00a0challenging yet promising future. Immunol Res. 2015;61:326\u201337.","journal-title":"Immunol Res"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-020-01669-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-020-01669-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,9]],"date-time":"2021-10-09T05:38:08Z","timestamp":1633757888000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-020-01669-y"}},"subtitle":["Single centre experience"],"short-title":[],"issued":{"date-parts":[[2020,5,25]]},"references-count":41,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1669"],"URL":"https:\/\/doi.org\/10.1007\/s00508-020-01669-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"type":"print","value":"0043-5325"},{"type":"electronic","value":"1613-7671"}],"subject":[],"published":{"date-parts":[[2020,5,25]]},"assertion":[{"value":"26 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical guidelines"}},{"value":"D.\u00a0Perkovi\u0107, M.\u00a0Petri\u0107, I.\u00a0Bo\u017ei\u0107, K.\u00a0Bori\u0107, D.\u00a0Marasovi\u0107 Krstulovi\u0107, M.\u00a0Radi\u0107 and D.\u00a0Martinovi\u0107 Kaliterna declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants or on human tissue were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1975 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}